Analysts forecast that OPKO Health, Inc. (NASDAQ:OPK) will report $304.07 million in sales for the current fiscal quarter, Zacks reports. Three analysts have issued estimates for OPKO Health’s earnings, with estimates ranging from $298.60 million to $307.10 million. OPKO Health reported sales of $428.10 million in the same quarter last year, which indicates a negative year-over-year growth rate of 29%. The company is scheduled to announce its next earnings report on Thursday, November 4th.
On average, analysts expect that OPKO Health will report full year sales of $1.58 billion for the current fiscal year, with estimates ranging from $1.54 billion to $1.61 billion. For the next fiscal year, analysts anticipate that the firm will report sales of $1.31 billion, with estimates ranging from $1.16 billion to $1.44 billion. Zacks’ sales averages are an average based on a survey of analysts that that provide coverage for OPKO Health.
OPKO Health (NASDAQ:OPK) last issued its quarterly earnings data on Thursday, July 29th. The biotechnology company reported ($0.03) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $0.02 by ($0.05). OPKO Health had a net margin of 3.71% and a return on equity of 4.21%. The business had revenue of $442.40 million for the quarter, compared to analysts’ expectations of $457.57 million.
In other OPKO Health news, CEO Phillip Md Et Al Frost purchased 100,000 shares of OPKO Health stock in a transaction that occurred on Tuesday, September 14th. The shares were bought at an average price of $3.46 per share, for a total transaction of $346,000.00. Following the acquisition, the chief executive officer now directly owns 3,068,951 shares in the company, valued at $10,618,570.46. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. 41.47% of the stock is currently owned by company insiders.
Large investors have recently modified their holdings of the company. Sequoia Financial Advisors LLC raised its holdings in shares of OPKO Health by 384.3% during the first quarter. Sequoia Financial Advisors LLC now owns 78,031 shares of the biotechnology company’s stock worth $335,000 after purchasing an additional 61,920 shares during the last quarter. Quantbot Technologies LP boosted its holdings in OPKO Health by 129.9% in the 1st quarter. Quantbot Technologies LP now owns 7,294 shares of the biotechnology company’s stock valued at $31,000 after purchasing an additional 4,122 shares during the last quarter. Teacher Retirement System of Texas lifted its holdings in shares of OPKO Health by 22.1% in the 1st quarter. Teacher Retirement System of Texas now owns 48,910 shares of the biotechnology company’s stock worth $210,000 after acquiring an additional 8,868 shares during the last quarter. Axiom Investment Management LLC purchased a new stake in OPKO Health during the 1st quarter worth approximately $124,000. Finally, Great West Life Assurance Co. Can increased its stake in OPKO Health by 25.0% during the 1st quarter. Great West Life Assurance Co. Can now owns 30,057 shares of the biotechnology company’s stock worth $128,000 after buying an additional 6,003 shares during the period. 27.56% of the stock is currently owned by institutional investors and hedge funds.
NASDAQ:OPK traded up $0.07 on Monday, hitting $3.80. The stock had a trading volume of 52,583 shares, compared to its average volume of 5,145,085. The company has a fifty day moving average price of $3.72 and a two-hundred day moving average price of $3.83. The company has a quick ratio of 1.36, a current ratio of 1.80 and a debt-to-equity ratio of 0.11. OPKO Health has a 1-year low of $3.02 and a 1-year high of $6.27. The stock has a market cap of $2.59 billion, a price-to-earnings ratio of 34.46 and a beta of 1.75.
OPKO Health Company Profile
OPKO Health, Inc, is a biopharmaceutical and diagnostics company, which engages in the provision of healthcare services. It operates through the following segments: Diagnostics and Pharmaceuticals. The Diagnostics segment include clinical laboratory operations of BioReference, as well as point-of-care operations.
Further Reading: How is net asset value different from market price?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for OPKO Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OPKO Health and related companies with MarketBeat.com's FREE daily email newsletter.